Inflammatory Factors and Thyroid Tumors: Exploring Their Diagnostic Value
Posted: Wednesday, May 19, 2021
Chronic inflammation appears to have a close relationship with thyroid tumor progression, according to research findings published in Technology in Cancer Research & Treatment. Researchers at Anhui Medical University, China, conducted a case control study to explore the diagnostic values of preoperative serum inflammatory factors in thyroid tumors. Using samples from 487 patients with thyroid tumors, Fubao Liu, MD, PhD, of the Department of Surgical Oncology, and colleagues compared the patients’ blood inflammatory factors with controls. They assessed the relationship of inflammatory factors with thyroid cancer and the potential of inflammatory factors as biomarkers for thyroid cancer.
“The preoperative inflammatory markers, such as C-reactive protein and interleukin-27 [IL-27], may help us differentially diagnose differentiated thyroid carcinoma. In addition, IL-27 may partially assist in distinguishing follicular thyroid carcinoma from papillary thyroid carcinoma, and neutrophil/lymphocyte-platelet/lymphocyte ratio may play a vital part during the differential diagnosis of papillary thyroid carcinoma,” the authors wrote.
Between June 2019 and January 2020, a total of 487 patients were enrolled in the study. All had undergone surgery and included 104 with follicular thyroid carcinoma, 200 with papillary thyroid carcinoma, and 83 with thyroid adenoma. A total of 217 healthy individuals receiving annual checkups at the same hospital served as healthy controls.
The study demonstrated that inflammation plays an important role in the progression of thyroid adenoma and differentiated thyroid carcinoma. The team will continue to study these relationships, particularly those between C-reactive protein, IL-27 and pathologic tissue, as well as prognosis of differentiated thyroid carcinoma.
Disclosure: The authors reported no conflicts of interest.